Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Respiratory Insufficiency
    • Peptide Agonists
      • TXP-11
    • Ongoing clinical studies
  • Investors
    • Capital Markets Day 2023
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
      • R&D Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Financial Reports

All categories
  • Annual reports
  • Interim reports
2019
  • 2023
  • 2022
  • 2021
  • 2020
  • 2018
  • 2017
  • 2016
  • All years
November 15, 2019

SynAct Pharma publishes Q3 2019 interim report (in Swedish)

August 30, 2019

SynAct Pharma publishes Q2 2019 interim report (in Swedish)

April 24, 2019

SynAct Pharma publishes Q1 2019 interim report (in Swedish)

April 17, 2019

SynAct publishes annual report and consolidated accounts for 2018

February 11, 2019

Year-end report for the financial year 2018

  • Investors
    • Capital Markets Day 2023
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
Torbjørn Bjerke
Torbjørn Bjerke
Chief Executive Officer
+46 727 44 41 58
[email protected]
Patrik Renblad, MSc.
Patrik Renblad, MSc.
Chief Financial Officer
+4670 747 97 68
[email protected]

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe